A randomised trial of zoledronic acid for osteoarthritis of the knee

Funding Activity

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Osteoarthritis (OA) is the most common form of arthritis and is increasing markedly due to an ageing population. Despite its large disease burden, there are currently no approved disease-modifying drugs available which modify structural progression of OA. The aim of this study is to compare zoledronic acid treatment to placebo on knee structural change and knee pain over two years. It is hypothesised that zoledronic acid will reduce cartilage loss, knee pain, and bone marrow lesion size.

Funded Activity Details

Start Date: 2013

End Date: 2017

Funding Scheme: Project Grants

Funding Amount: $989,238.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Rheumatology and Arthritis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity